Presentations by Event

Characterization of colistin-resistant (COL-R) Acinetobacter baumannii-calcoaceticus complex (ABC) isolates from a recent global phase 3 trial (ATTACK)

Samir Moussa, Sarah McLeod and Alita Miller (IDWeek, 2022)

Program(s): durlobactam (etx2514)

Efficacy and safety of sulbactam-durlobactam are consistent across regions in the global ATTACK phase 3 trial in the treatment of carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC) infections

Alita Miller, Adam Shapiro, Sarah McLeod, Khurram Rana, Drew Lewis and David Altarac (IDWeek, 2022)

Program(s): durlobactam (etx2514)

Sulbactam-durlobactam (SUL-DUR) versus colistin therapy in patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections: A detailed safety review from the pivotal phase 3, global, randomized, active-controlled trial (ATTACK)

Drew Lewis, Khurram Rana, Melissa Steidler, Gabrielle Poirier and David Altarac (IDWeek, 2022)

Program(s): durlobactam (etx2514)

Microbiologic and clinical outcome concordance in the global phase 3 ATTACK trial: sulbactam-durlobactam (SUL-DUR) versus colistin therapy in patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections

David Altarac, Alita Miller, Sarah McLeod, Adam Shapiro, Khurram Rana, Drew Lewis, Gabrielle Poirier, and Daria Chabas (IDWeek, 2022)

Program(s): durlobactam (etx2514)

Efficacy of sulbactam-durlobactam (SUL-DUR) versus colistin in patients with extensively drug-resistant (XDR) and pan-drug resistant (PDR) Acinetobacter baumannii-calcoaceticus complex (ABC) infections

Alita Miller, Sarah McLeod, Adam Shapiro, Khurram Rana, Drew Lewis, Gabrielle Poirier, Daria Chabas and David Altarac (IDWeek, 2022)

Program(s): durlobactam (etx2514)

Population pharmacokinetic (PPK), pharmacokinetic/pharmacodynamic attainment (PTA), clinical pharmacokinetic/pharmacodynamic (PK/PD) analyses for sulbactam-durlobactam (SUL-DUR) to support dose selection for the treatment of Acinetobacter baumannii–calcoaceticus complex (ABC) infections

Sujata Bhavnani, Christopher Rubino, Jeffrey Hammel, Anthony Cammarata, Kajal Larson, Sarah McLeod, Alita Miller, Paul Ambrose, Ruben Tommasi and John O'Donnell (IDWeek, 2022)

Program(s): durlobactam (etx2514)

ETX0462, a novel non-β-lactam PBP inhibitor, does not induce AmpC expression

Samir Moussa and Alita Miller (ASM Microbe, 2022)

Program(s): etx0462

In vitro activity of sulbactam-durlobactam against recent clinical Acinetobacter baumannii-calcoaceticus complex isolates from the United States

Adam Shapiro, Sarah McLeod, Samir Moussa, Meredith Hackel, Alita Miller (ASM Microbe, 2022)

Program(s): durlobactam (etx2514)

Potent activity of sulbactam-durlobactam against pan-drug resistant Acinetobacter baumannii-calcoaceticus complex (ABC) isolates from a recent 5-year surveillance study (2016-2020)

Sarah McLeod, Alita Miller, Meredith Hackel, Daniel Sahm (ASM Microbe, 2022)

Program(s): durlobactam (etx2514)

In vitro activity of sulbactam-durlobactam against Acinetobacter baumannii clinical isolates collected in 2020 from China

Sarah McLeod, Meredith Hackel, Alita Miller (ASM Microbe, 2022)

Program(s): durlobactam (etx2514)

In vitro activity of sulbactam-durlobactam in combination with other antimicrobial agents

Nicole Carter, Sarah McLeod, Adam Shapiro and Alita Miller (ASM Microbe, 2022)

Program(s): durlobactam (etx2514)

Sulbactam-durlobactam is bactericidal against clinical isolates of Acinetobacter baumannii

Nicole Carter, Sarah McLeod, Adam Shapiro and Alita Miller (ASM Microbe, 2022)

Program(s): durlobactam (etx2514)

Sulbactam-durlobactam (SUL-DUR), a targeted β-lactam/β-lactamase inhibitor, for MDR Acinetobacter infections

Sarah McLeod and Alita Miller (ASM Microbe, 2022)

Program(s): durlobactam (etx2514)

ETX0462, a novel, non-β-lactam PBP inhibitor, has potent antibacterial activity against a panel of geographically diverse Gram-negative bacterial clinical isolates

John O'Donnell, Ramkumar Iyer, Thomas Durand-Reville, Ruben Tommasi, Stephen Hawser, Cyntia De Piano, Thomas Valmont, Ian Morrissey, Alita Miller (ASM Microbe, 2022)

Program(s): etx0462

Pharmacokinetics/pharmacodynamics of the β-lactamase inhibitor, durlobactam, in combination with sulbactam against Acinetobacter baumannii-calcoaceticus Complex

John O'Donnell, Brian Van Scoy, Sujata Bhavnani, Paul Ambrose, Sarah McLeod and Ruben Tommasi (ASM Microbe, 2022)

Program(s): durlobactam (etx2514)

Sulbactam-durlobactam is associated with lower mortality from index Acinetobacter infections in the ATTACK phase 3 registrational trial

David Altarac, Adam Shapiro , Khurram Rana, Drew Lewis (ATS, 2022)

Program(s): durlobactam (etx2514)